

# Ocaliva (obeticholic acid) Prior Authorization with Quantity Limit Program Summary

## FDA APPROVED INDICATIONS AND DOSAGE<sup>1</sup>

Agent(s)	Indication(s)	Dosage
<b>Ocaliva®</b> (obeticholic acid)  Tablet	Treatment of adult patients with primary biliary cholangitis (PBC) <ul style="list-style-type: none"> <li>- without cirrhosis, or</li> <li>- with compensated cirrhosis who do not have evidence of portal hypertension</li> </ul> either in combination with ursodeoxycholic acid (UDCA) with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA	The recommended dosage for PBC patients without cirrhosis or with compensated cirrhosis who do not have evidence of portal hypertension, who have not achieved an adequate biochemical response to an appropriate dosage of UDCA for at least 1 year or are intolerant to UDCA: <ul style="list-style-type: none"> <li>- Start with a dosage of 5 mg once daily for the first 3 months</li> <li>- After the first 3 months, for patients who are tolerating Ocaliva and have not achieved an adequate reduction in ALP and/or total bilirubin, increase to a maximum dosage of 10 mg once daily</li> </ul>

## CLINICAL RATIONALE

### Primary Biliary Cholangitis

Primary biliary cholangitis (PBC), formerly known as primary biliary cirrhosis, is an autoimmune chronic progressive cholestatic liver disease that predominantly affects women. PBC is characterized by a T-lymphocyte-mediated attack on small intralobular bile ducts eventually leading to their gradual destruction and disappearance, ultimately leading to cirrhosis and liver failure. Patients with PBC may be asymptomatic, or they may present with symptoms such as fatigue, pruritus, jaundice, cholestatic liver enzymes, and signs and symptoms of cirrhosis. Common laboratory test abnormalities in patients with PBC include elevated alkaline phosphatase (ALP), antimitochondrial antibodies (AMA), antinuclear antibodies (ANA), and hyperlipidemia.<sup>2,3,5</sup>

According to the American Association for the Study of Liver Diseases (AASLD) 2018 Practice Guidance on Primary Biliary Cholangitis, the diagnosis of PBC is generally based on the presence of at least two of the following criteria:<sup>2</sup>

1. Biochemical evidence of cholestasis based on alkaline phosphatase (ALP) elevation
2. Presence of AMA (with a titer greater than 1:80), OR if AMA is negative (or present only in low titer [less than or equal to 1:80]), other PBC-specific auto antibodies including sp100 or gp210
3. Histologic evidence of PBC (nonsuppurative destruction cholangitis and destruction of interlobular bile ducts)

Management of PBC includes treatment of symptoms and complications that result from chronic cholestasis and suppression of the underlying pathogenic process (destruction of small intralobular hepatic bile ducts). Ursodeoxycholic acid (ursodiol, UDCA) is first-line therapy for PBC.<sup>2,4</sup> UDCA improves biochemical indices and delays histologic progression, ultimately enhancing survival. UDCA has minimal side effects and is generally well tolerated. An inadequate response to UDCA, as defined by the Toronto criteria, is an alkaline phosphatase level greater than 1.67 times the upper limit of normal after one year of UDCA. In patients with compensated or no cirrhosis and with an inadequate response to UDCA, obeticholic acid can be used in

combination with UDCA or it can be used as monotherapy in patients who are unable to tolerate UDCA.<sup>2</sup>

Treatment response is monitored using liver biochemical tests. Specifically, serum ALP and total bilirubin predict outcomes in this context. Improvement is typically observed within a few weeks, and 90% of the improvement usually occurs by 6-9 months; about 20% of patients achieve normalization of liver biochemistries after two years.<sup>2,4</sup>

### **Efficacy**

Ocaliva (obeticholic acid) is a farnesoid X receptor (FXR) agonist. FXR is a nuclear receptor expressed in the liver and intestine. FXR is a key regulator of bile acid, inflammatory, fibrotic, and metabolic pathways. FXR activation decreases the intracellular hepatocyte concentrations of bile acids by suppressing *de novo* synthesis from cholesterol as well as by increased transport of bile acids out of hepatocytes. These mechanisms limit the overall size of the circulating bile acid pool while promoting choleresis, thus reducing hepatic exposure to bile acids.<sup>1</sup>

Obeticholic acid was approved based on a randomized, double-blind, placebo controlled, 12-month trial in patients with PBC (POISE – NCT01473524). Inclusion criteria included an intolerance to UDCA or a suboptimal biochemical response to UDCA after 12 months of UDCA. Suboptimal biochemical response (treatment failure) was defined as ALP 1.67 times the upper limit of normal (ULN) or greater, and/or total bilirubin greater than the ULN but less than 2 times ULN.<sup>1,6</sup> Of note, the suboptimal biochemical response, defined for the study inclusion, was based on a modification of the Toronto criteria.<sup>5,6</sup> Primary endpoints for responders were defined as 3 criteria: ALP less than 1.67 times the ULN, total bilirubin less than or equal to ULN, and an ALP decrease of at least 15%.<sup>1</sup>

### **Safety**

Ocaliva has a boxed warning of hepatic decompensation and failure in primary biliary cholangitis patients with cirrhosis. Hepatic decompensation and failure, sometimes fatal or resulting in liver transplant, have been reported in primary biliary cholangitis (PBC) patients with either compensated or decompensated cirrhosis. Ocaliva is contraindicated in PBC patients with decompensated cirrhosis, a prior decompensation event, or with compensated cirrhosis who have evidence of portal hypertension.<sup>1</sup>

Ocaliva is contraindicated in patients with complete biliary obstruction; decompensated cirrhosis (e.g., Child-Pugh Class B or C) or a prior decompensation event; compensated cirrhosis who have evidence of portal hypertension (e.g., ascites, gastroesophageal varices, persistent thrombocytopenia).<sup>1</sup>

### **References**

1. Ocaliva prescribing information. Intercept Pharmaceuticals, Inc. May 2021.
2. Lindor KD, Bowlus CL, Boyer J, et al. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (AASLD).
3. Poupon R, et al. Clinical Manifestations, Diagnosis, and Prognosis of Primary Biliary Cholangitis (Primary Biliary Cirrhosis). UpToDate. Last updated January 2021. Literature review current through September 2021. Accessed October 2021.
4. Poupon R, et al. Overview of the Management of Primary Biliary Cholangitis. UpToDate. Last updated May 2021. Literature review current through September 2021. Accessed October 2021.
5. European Association for the Study of the Liver (EASL) 2017 Clinical Practice Guidelines: The Diagnosis and Management of Patients with Primary Biliary Cholangitis.
6. Corpechot C, Poupon R, Chazouilleres O. New Treatments/Targets for Primary Biliary Cholangitis. *J Hepatol Reports*. 2019;1(3):203-213.

## Ocaliva (obeticholic acid) Prior Authorization with Quantity Limit

### TARGET AGENT(S)

Ocaliva® (obeticholic acid)

Brand (generic)	GPI	Multisource Code	Quantity Limit (per day or as listed)
<b>Ocaliva (obeticholic acid)</b>			
5 mg tablet	52750060000320	M, N, O, or Y	1 tablet
10 mg tablet	52750060000330	M, N, O, or Y	1 tablet

### PRIOR AUTHORIZATION CRITERIA FOR APPROVAL

#### Initial Evaluation

**Target Agent(s)** will be approved when ALL of the following are met:

1. ONE of the following:

a. The patient has a diagnosis of primary biliary cholangitis (PBC) and ALL of the following:

i. Diagnosis was confirmed by at least TWO of the following:

1. There is biochemical evidence of cholestasis with an alkaline phosphatase (ALP) elevation
2. Presence of antimitochondrial antibody (AMA): a titer greater than 1:80
3. If the AMA is negative or present only in low titer (less than or equal to 1:80), presence of other PBC-specific autoantibodies, including sp100 or gp210
4. Histologic evidence of nonsuppurative destruction cholangitis and destruction of interlobular bile ducts

**AND**

ii. The prescriber has measured the patient's baseline alkaline phosphatase (ALP) level and total bilirubin level (prior to therapy with the requested agent)

**AND**

iii. ONE of the following:

1. The patient does NOT have cirrhosis

**OR**

2. The patient has compensated cirrhosis with NO evidence of portal hypertension

**AND**

iv. ONE of the following:

1. BOTH of the following:

a. The patient has tried and had an inadequate response after at least 1 year of therapy with ursodeoxycholic acid (UDCA) (inadequate response defined as ALP greater than or equal to 1.67-times the upper limit of normal [ULN], and/or total bilirubin greater than the ULN but less than 2x ULN, after 1 year of treatment with UDCA)

**AND**

b. The patient will continue treatment with ursodeoxycholic acid (UDCA) with the requested agent

**OR**

2. The patient has an intolerance, FDA labeled contraindication, or hypersensitivity to ursodeoxycholic acid (UDCA)

**OR**

- b. The patient has another FDA approved indication for the requested agent

**AND**

2. ONE of the following:

- a. The patient's age is within FDA labeling for the requested indication for the requested agent

**OR**

- b. The prescriber has provided information in support of using the requested agent for the patient's age for the requested indication

**AND**

3. The prescriber is a specialist in the area of the patient's diagnosis (e.g., gastroenterologist, hepatologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**AND**

4. The patient does NOT have any FDA labeled contraindications to the requested agent

**AND**

5. ONE of the following:

- a. The requested quantity (dose) does NOT exceed the program quantity limit

**OR**

- b. ALL of the following:

- i. The requested quantity (dose) is greater than the program quantity limit

**AND**

- ii. The requested quantity (dose) does NOT exceed the maximum FDA labeled dose for the requested indication

**AND**

- iii. The requested quantity (dose) cannot be achieved with a lower quantity of a higher strength that does not exceed the program quantity limit

**Length of Approval:** 12 months

### **Renewal Evaluation**

**Target Agent(s)** will be approved when ALL of the following are met:

1. The patient has been previously approved for the requested agent through the plan's Prior Authorization process

**AND**

2. ONE of the following:

- a. For primary biliary cholangitis (PBC), ALL of the following:

- i. ONE of the following:

1. The patient does NOT have cirrhosis

**OR**

2. The patient has compensated cirrhosis with NO evidence of portal hypertension

**AND**

- ii. ONE of the following:

1. The requested agent will be used in combination with ursodeoxycholic acid (UDCA)

**OR**

2. The patient has an intolerance, FDA labeled contraindication, or hypersensitivity to ursodeoxycholic acid (UDCA)

**AND**

iii. The patient has had an alkaline phosphatase (ALP) decrease of greater than or equal to 15% from baseline (prior to therapy with the requested agent) AND ALP is less than 1.67-times the upper limit of normal (ULN)

**AND**

iv. The patient's total bilirubin is less than or equal to the upper limit of normal (ULN)

**OR**

b. For another FDA approved indication, the patient has had clinical benefit with the requested agent

**AND**

3. The prescriber is a specialist in the area of the patient's diagnosis (e.g., gastroenterologist, hepatologist) or the prescriber has consulted with a specialist in the area of the patient's diagnosis

**AND**

4. The patient does NOT have any FDA labeled contraindications to the requested agent

**AND**

5. ONE of the following:

a. The requested quantity (dose) does NOT exceed the program quantity limit

**OR**

b. ALL of the following:

i. The requested quantity (dose) is greater than the program quantity limit

**AND**

ii. The requested quantity (dose) does NOT exceed the maximum FDA labeled dose for the requested indication

**AND**

iii. The requested quantity (dose) cannot be achieved with a lower quantity of a higher strength that does not exceed the program quantity limit

**Length of Approval:** 12 months